Last updated: February 21, 2026
What is the Product?
NDC 60505-4377 refers to Entyvio (vedolizumab), a biologic therapy used for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. It received FDA approval for moderate to severe cases refractory to standard treatments, including corticosteroids and immunomodulators.
Market Size and Adoption Trends
The U.S. inflammatory bowel disease (IBD) market is growing, driven by increased diagnosis rates and expanding treatment indications for biologics. Key market drivers include unmet patient needs, patent exclusivity periods, and adoption of advanced biologic agents.
Market Size (2022-2027 Forecast)
| Year |
Estimated Market Size (USD billions) |
CAGR (%) |
| 2022 |
3.2 |
N/A |
| 2023 |
3.5 |
9.4 |
| 2024 |
3.8 |
8.6 |
| 2025 |
4.2 |
10.5 |
| 2026 |
4.6 |
9.5 |
| 2027 |
5.0 |
8.7 |
Source: IQVIA Analytics (2022).
Key Commercial Factors
- Patient population: Approximate 1.2 million U.S. patients diagnosed with IBD, with about 20-30% on biologic therapy.
- Market penetration: Estimated 25-30% of eligible patients currently on vedolizumab, with increasing adoption due to physician familiarity and formulations.
- Competitive landscape: Includes infliximab, adalimumab, ustekinumab, and ozanimod. Vedolizumab has a favorable safety profile, promoting continued growth.
Pricing Analysis and Projections
Current Pricing Landscape (2023)
- List Price: Approximate annual cost per patient is $35,000 - $45,000 for intravenous infusions.
- Reimbursement and Net Price: Discounts, rebates, and payer negotiations reduce net revenue by 20-30%.
- Comparison: Ustekinumab and infliximab price ranges are similar, with infliximab possibly costing more due to broader indications.
Price Trends (2023-2027)
| Year |
Estimated List Price per Course (USD) |
Estimated Net Price (USD) |
| 2023 |
40,000 |
28,000 |
| 2024 |
41,000 |
28,700 |
| 2025 |
42,000 |
29,400 |
| 2026 |
43,000 |
30,100 |
| 2027 |
44,000 |
30,800 |
Projection assumes moderate annual list price increases aligned with inflation and drug costs, with persistent discounts.
Regulatory and Market Dynamics Impacting Price
- Patent protections (original patent expired in 2014, with biosimilars entering the market in 2024).
- Biosimilar competition: Several biosimilars for infliximab have entered the U.S. market, pressuring biologic prices. Vedolizumab’s exclusivity extends due to patent extensions and formulation improvements.
- FDA approval extensions and label expansions may facilitate market growth and justify price adjustments.
Key Risks and Opportunities
- Risks: Biosimilar entry decreasing revenue, payer pushbacks on high prices, and evolving treatment guidelines favoring small molecule therapies.
- Opportunities: Increasing off-label uses, combination therapies, and potential new indications could sustain sales.
- Impact of biosimilar competition could reduce list prices by 15-25% over the next two years, with net prices decreasing proportionally.
Conclusion
- The IBD biologics market is trending upward, with vedolizumab holding a solid share.
- Prices are expected to rise modestly before biosimilar pressure intensifies post-2024.
- Net revenue projections suggest a stabilizing market with potential for slight declines due to biosimilars and payer negotiations.
Key Takeaways
- The IBD biologics market is projected to grow at a CAGR of ~8.7% through 2027, reaching USD 5 billion.
- List prices for vedolizumab are expected to increase by approximately USD 1,000 annually, with net prices growing slightly slower due to discounts.
- Biosimilar entry will put downward pressure on prices starting from 2024 but will not immediately eliminate vedolizumab's market share.
- Market expansion relies on newly approved indications and increased physician adoption.
- Payer negotiations and biosimilar competition are the primary factors influencing future pricing strategies.
FAQs
1. How does the market penetration of vedolizumab compare to other biologics?
Currently, it covers about 25-30% of the eligible IBD population, trailing infliximab and adalimumab, but gaining share due to its safety profile.
2. What is the impact of biosimilars on vedolizumab pricing?
Biosimilars for infliximab and adalimumab have decreased prices in the market by 15-25%. Vedolizumab may experience similar pressure, but patent protections delay immediate biosimilar entry.
3. How are reimbursement trends expected to change?
Reimbursement negotiations aim to maintain market share amid increasing biosimilar competition, potentially leading to higher net discounts.
4. Are there upcoming regulatory approvals that could alter the market?
New indications for vedolizumab, such as pediatric use or other autoimmune conditions, could expand sales and justify price increases.
5. What is the outlook for generic or biosimilar competition for vedolizumab?
Biosimilars are likely to enter the U.S. market post-2024, introducing price competition but not immediately replacing vedolizumab for all indications.
References
- IQVIA. (2022). US prescription drug market report.
- FDA. (2022). Vedolizumab (Entyvio) prescribing information.
- MarketWatch. (2023). Biologics market trends and forecasts.
- Statista. (2023). Biologic drugs pricing and market data.
- EvaluatePharma. (2022). 2022 Biologic drugs market analysis.
[1] IQVIA Analytics. (2022). U.S. prescription drug market insights.
